Hostname: page-component-54dcc4c588-sdd8f Total loading time: 0 Render date: 2025-10-07T05:29:21.792Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of the age of onset and duration of schizophrenia on the quality of treatment adherence

Published online by Cambridge University Press:  26 August 2025

A. Rami
A. Rami*
Affiliation:
Razi Hospital, Manouba, Tunisia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Schizophrenia is a chronic, frequent, and disabling psychiatric condition. The prognosis is more severe in the absence of treatment.

Objectives

The aims of our study were to evaluate the quality of treatment adherence and the Impact of the age of onset and duration of schizophrenia on the quality of treatment adherence and to assess the implication of these factors as predictors of poor adherence.

Methods

We conducted a cross-sectional and analytical study. We recruited 150 patients with schizophrenia treated at Razi Hospital of Manouba, divided into 113 patients with good adherence compared to 37 patients with poor adherence. We used the Medical Adherence Report Scale (MARS) to assess the quality of therapeutic adherence.

Results

The average age of onset of the illness was 22.91 ± 4.6 years, with extremes ranging from 13 to 36 years.

The average duration of the illness in the patients in our series was 17 years, with extremes ranging from two to 42 years.

The average duration of untreated psychosis was two years, with a median of 12 months and extremes ranging from one month to 20 years.

A statistically significant association was found between the duration of untreated psychosis and the quality of treatment adherence (p=0.003).

Neither the age of onset of the illness nor its duration had any influence on the quality of patient adherence.

Conclusions

To prevent poor treatment adherence, a systematic screening for predictive factors and adequate management of schizophrenia would be imperative.

Disclosure of Interest

None Declared

Information

Type
Abstract
Information
European Psychiatry , Volume 68 , Special Issue S1: Abstracts of the 33rd European Congress of Psychiatry , April 2025 , pp. S1113
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.